AAAAAA
Results:
1-8
|
Results: 8
Authors:
Egan, LJ
Tremaine, WJ
Mays, DC
Lipsky, JJ
Sandborn, WJ
Citation: Lj. Egan et al., Clinical outcome and pharmacokinetics after addition of low-dose cyclosporine to methotrexate: A case study of five patients with treatment-resistantinflammatory bowel disease, INFLAMM B D, 6(4), 2000, pp. 286-289
Authors:
Egan, LJ
Murray, JA
Citation: Lj. Egan et Ja. Murray, New perspectives in gastric acid suppression: Genetic polymorphisms predict the efficacy of proton pump inhibitors, DIGEST DIS, 18(2), 2000, pp. 58-63
Authors:
Egan, LJ
Baron, TH
Citation: Lj. Egan et Th. Baron, Endoscopic removal of an embedded biliary Wallstent by piecemeal extraction, ENDOSCOPY, 32(6), 2000, pp. 492-494
Authors:
Romero, Y
Egan, LJ
Murray, JA
Citation: Y. Romero et al., Reflux esophagitis: Healed! Now what?, AM J GASTRO, 95(2), 2000, pp. 337-338
Authors:
Egan, LJ
Sandborn, WJ
Mays, DC
Tremaine, WJ
Lipsky, JJ
Citation: Lj. Egan et al., Plasma and rectal adenosine in inflammatory bowel disease: Effect of methotrexate, INFLAMM B D, 5(3), 1999, pp. 167-173
Authors:
Egan, LJ
Sandborn, WJ
Tremaine, WJ
Leighton, JA
Mays, DC
Pike, MG
Zinsmeister, AR
Lipsky, JJ
Citation: Lj. Egan et al., A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis, ALIM PHARM, 13(12), 1999, pp. 1597-1604
Authors:
Egan, LJ
Mays, DC
Huntoon, CJ
Bell, MP
Pike, MG
Sandborn, WJ
Lipsky, JJ
McKean, DJ
Citation: Lj. Egan et al., Inhibition of interleukin-1-stimulated NF-kappa B RelA/p65 phosphorylationby mesalamine is accompanied by decreased transcriptional activity, J BIOL CHEM, 274(37), 1999, pp. 26448-26453
Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease
Authors:
Egan, LJ
Sandborn, WJ
Mays, DC
Tremaine, WJ
Fauq, AH
Lipsky, JJ
Citation: Lj. Egan et al., Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease, CLIN PHARM, 65(1), 1999, pp. 29-39
Risultati:
1-8
|